Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 04 Jun 2019 According to a trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology, from August 2018, 58 patients have been enrolled in this trial.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.